niertransplantatie, kidney transplantation lymfklieren, lymph nodes alemtuzumab alloreactiviteit, alloreactivity veroudering immuunsysteem, ageing of the immune system T-folliculaire helper cellen, T-follicular helper cells
Conditions
Interventions
harvesting of locoregional lymph node during kidney transplantation.
Sponsors
Erasmus Medical Center
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet the following criteria: - Adult patients receiving a deceased or living kidney transplant in the Erasmus Medical Center Rotterdam, The Netherlands and: - Group 1: o Historical PRA > 6% and/ or: o HLA MM ¡Ý4 on A, B and DR loci - Group 2: o Recipients of an ABO-incompatible kidney graft. Patients have to give written informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - ABO-compatible HLA identical living-related transplant recipients. - Patients unable to give written informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary objective of this study is to determine the prognostic characteristics for BPAR in the first three months after kidney transplantation, as assessed in the lymphocyte composition of the lymph node in immunologically high-risk kidney transplantation. | — |
Secondary
| Measure | Time frame |
|---|---|
| - to capture global composition of lymph node versus blood leukocyte subsets in renal insufficiency. - to compare the immunological ageing profile of T cells in the peripheral blood to the T cells derived from the lymph node. - to assess whether pre-transplant frequencies of lymph node derived TFH, T and B cells predict BPAR. - to assess differences in lymphocyte composition of lymph nodes in alemtuzumab treated versus untreated patients both in single cell suspension and within the tissue. (ABO-incompatible kidney transplant recipients receive alemtuzumab induction therapy three weeks before transplantation). | — |
Contacts
Public ContactA.E. Weerd, de
Internist-nephrologist Erasmus Medical Center Room D-411 Postbus 2040
Outcome results
None listed